Closing in on Myc inhibition: a marathon sprint finish?

by VHIO

We have come a long way to get to this point, with many twists and unexpected turns. A voyage which we have been fortunate to navigate alongside many other expert teams, investigators at biotech and p...

Read more

A molecular classification predicts the prognosis and the benefit of a cell cycle inhibitor in metastatic breast cancer

by Fundació Clínic per a la Recerca Biomèdica

In a study published in the Journal of Clinical Oncology, researchers from the Hospital Clínic-IDIBAPS-UB and SOLTI showed the predictive capacity of the 4 molecular subtypes of breast cancer (Lumina...

Read more

XOMA and Inveready Acquires Royalty Interest Position in Six Clinical-Stage Assets from Palobiofarma

by Palobiofarma

XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L.One of the asse...

Read more

WHO recommends an integrase inhibitor as preferred HIV treatment option in all populations

by Fundació Bancària 'la Caixa'

The WHO Guideline Development Group decided to recomment dolutegravir as the preferred first-line and second-line treatment for all populations, in contrast with initial studies.

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Umbilical cord blood dispels inflammatio...

by Secuvita

A study carried out by the StemCyte laboratory and published on the Pa...

Photos Stream